ClinicalTrials.gg
RecruitingNCT05528055Updated Sep 6, 2022

A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of SCR-6920 capsule and SCR-6920 capsule in Solid Tumor and Non Hodgkin Lymphoma, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-06.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 196 studies in Lymphoma, Non-Hodgkin with a site in China — 83 open to participants now, 110 under way, 14 of them phase 3. Lymphoma, Non-Hodgkin · China.

Planned enrollment
45th of 183
122 · median 58
Started
2022
with 27 others
Phase 1
79 of 196
33 open now
Primary completion
2027-10
later than 74 of 109 live
Registered
118th of 196
by date

Among the 196 studies in Lymphoma, Non-Hodgkin with a site in China, this one is the 45th largest by planned enrollment of the 183 interventional ones that give a count, is one of 28 that started in 2022, is one of 79 in phase 1, reaches primary completion later than 74 of the 109 other live ones, and was the 118th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

83 of the 196 studies in Lymphoma, Non-Hodgkin with a site in China are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Lymphoma, Non-Hodgkin with a site in China, or all of them as a file.
02

Study summary

A Phase 1, open label, multi center, dose escalation and expansion study will assess the safety, tolerability, PK, and preliminary efficacy of SCR-6920 capsule in participants with advanced malignant tumors. The purpose of the study is to identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D), and to confirm the tolerability and preliminary efficacy of SCR-6920 in participants with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma(NHL).

03

Conditions studied

  • Solid Tumor
  • Non Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed locally advanced or solid tumors or histopathologically confirmed NHL
  • solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
  • At least one evaluable or (as defined in the protocol).
  • Performance Status 0 or 1.
  • ≥12 weeks.
  • Adequate organ function (as defined in the protocol).
  • Reproductive criteria (as defined in the protocol).

Exclusion criteria

Exclusion Criteria:

  • Any gastrointestinal (GI) abnormalities that may alter absorption.
  • Major surgery, systemic anti-cancer therapy or drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
  • Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
  • hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
  • History of a second within 2 years (as defined in the protocol).
  • Active uncontrolled or symptomatic lung disease (as defined in the protocol).
  • Intracranial hypertension or active uncontrolled or symptomatic .
  • Known or suspected to study medications.
  • Known active uncontrolled or symptomatic CNS metastases.
  • The investigator determined that the patient should not participate in the study.
  • Known mental illness or substance abuse that may disrupt therapy.
  • Clinically significant cardiac abnormalities (as defined in the protocol).
  • Gestating or Lactating women.
  • Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
  • The patient is currently using a drug known to be a strong inhibitor or inducer of .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    Dose escalation

    Participants will receive SCR-6920 capsule orally at escalating doses, till the maximum tolerated dose level is reached, and the recommended phase 2 dose(RP2D) will be determined.

    Drug: SCR-6920 capsule

  • Experimental
    Dose expansion: non small cell lung cancer(NSCLC)

    Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose

    Drug: SCR-6920 capsule

  • Experimental
    Dose expansion: NHL

    Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis

    Drug: SCR-6920 capsule

  • Experimental
    Dose expansion: solid tumors

    Participants will receive SCR-6920 capsule orally at the recommended phase 2 dose on a continuous basis

    Drug: SCR-6920 capsule

Interventions

  • DrugSCR-6920 capsule

    SCR-6920 capsule will be oral administered once daily at escalating doses on a continuous basis

    Also known as: PRMT5 inhibitor

  • DrugSCR-6920 capsule

    SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

    Also known as: PRMT5 inhibitor

  • DrugSCR-6920 capsule

    SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

    Also known as: PRMT5 inhibitor

  • DrugSCR-6920 capsule

    SCR-6920 capsule will be oral administered once daily at the recommended phase 2 dose on a continuous basis

    Also known as: PRMT5 inhibitor

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity(DLT)

    DLT will be evaluated within 28 days since first dose. The number of DLTs will be used to determine the maximum tolerated dose (MTD).

    Time frame: Up to 28 days

  2. Overall Response Rate (ORR)

    Participants with solid tumor: ORR based on RECIST1.1 criteria; Participants with NHL: ORR based on Lugano criteria

    Time frame: Up to approximately 1 years

Secondary outcomes

  1. Number of participants with any adverse events (AEs), serious adverse events (SAEs), withdrawal due to AEs, dose interruptions and reductions

    All AEs, SAEs and dose modifications will be collected. Adverse events as characterized by type, severity, timing and relationship to study therapy. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

    Time frame: Up to approximately 1 years

  2. Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG), physical examination and organ-specific parameters.

    Blood and urine samples will be collected for analysis of lab parameters. Vital signs, electrocardiogram (ECG), physical examinations and organ-specific parameters will be collected at specified time points. Number of participants with clinically significant changes in laboratory parameters, vital signs, electrocardiogram (ECG), physical examination and organ-specific parameters will be reported.

    Time frame: Up to approximately 1 years

  3. Pharmacokinetic Parameters: Area Under the Curve (AUC)

    Blood samples will be collected at given time points to determine the AUC (0-t) and AUC (0-inf) of SCR-6920

    Time frame: Up to approximately 1 years

  4. Pharmacokinetic Parameters: Maximum Concentration (Cmax)

    Blood samples will be collected at given time points to determine the Cmax of SCR-6920.

    Time frame: Up to approximately 1 years

  5. Pharmacokinetic Parameters: Trough Concentration (Ctrough)

    Blood samples will be collected at given time points to determine the Ctrough of SCR-6920.

    Time frame: Up to approximately 1 years

  6. Pharmacokinetic Parameters: Time to Maximum Concentration (Tmax)

    Blood samples will be collected at given time points to determine the Tmax of SCR-6920.

    Time frame: Up to approximately 1 years

  7. Pharmacokinetic Parameters: Terminal elimination half life (t1/2)

    Blood samples will be collected at given time points to determine the t1/2 of SCR-6920.

    Time frame: Up to approximately 1 years

  8. Change from Baseline in symmetrical arginine dimethylation (SDMA) as a PD measure

    Evaluation of change from baseline in SDMA, a PD biomarker of PRMT5 inhibition.

    Time frame: Up to approximately 1 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Oct 2027, 65 months after the start.

Of 163 industry-sponsored phase 1 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 70. This study's planned 65 months is above that.

Counting every sponsor, half of 286 studies reached it within 55 months; a quarter within 38 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
Sep 6, 2022
StartActual
May 18, 2022
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Sep 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05528055
Responsible party
Sponsor
First posted
Sep 6, 2022
Start date
May 18, 2022
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 6, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion